Mody, Kinjal

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Burris, H. A., Patel, M. R., Cho, D. C., Clarke, J. M., Gutierrez, M., Zaks, T. Z., Frederick, J., Hopson, K., Mody, K., Binanti-Berube, A., et al. (2019) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 144

798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

Bauman, J., Burris, H., Clarke, J., Patel, M., Cho, D., Gutierrez, M., Julian, R., Scott, A., Cohen, P., Frederick, J., et al. (2020) · Late-breaking abstracts

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 54